SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ane Løvli Stav, Dag Aarsland, Krisztina Kunszt Johansen, Erik Hessen, Eirik Auning, Tormod Fladby, Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 7, 758

    CrossRef

  2. 2
    M. Börger, S. Funke, M. Bähr, F. Grus, P. Lingor, Biomarker sources for Parkinson's disease: Time to shed tears?, Basal Ganglia, 2015,

    CrossRef

  3. 3
    Chin-Hsien Lin, Ruey-Meei Wu, Biomarkers of cognitive decline in Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 5, 431

    CrossRef

  4. 4
    Tara M. Madhyastha, Mary K. Askren, Peter Boord, Jing Zhang, James B. Leverenz, Thomas J. Grabowski, Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease, Movement Disorders, 2015, 30, 8
  5. 5
    Lynn M. Bekris, Debby W. Tsuang, Elaine R. Peskind, Chang E. Yu, Thomas J. Montine, Jing Zhang, Cyrus P. Zabetian, James B. Leverenz, Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease, Movement Disorders, 2015, 30, 7
  6. 6
    Yue Yang, C. Dirk Keene, Elaine R. Peskind, Douglas R. Galasko, Shu-Ching Hu, Eiron Cudaback, Angela M. Wilson, Ge Li, Chang-En Yu, Kathleen S. Montine, Jing Zhang, Geoffrey S. Baird, Bradley T. Hyman, Thomas J. Montine, Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease, Journal of Neuropathology & Experimental Neurology, 2015, 74, 7, 672

    CrossRef

  7. 7
    Changqin Liu, Brenna Cholerton, Min Shi, Carmen Ginghina, Kevin C. Cain, Peggy Auinger, Jing Zhang, CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 3, 271

    CrossRef

  8. 8
    Tara M. Madhyastha, Mary K. Askren, Jing Zhang, James B. Leverenz, Thomas J. Montine, Thomas J. Grabowski, Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson’s disease, Brain, 2015, awv189

    CrossRef

  9. 9
    Erica J. Melief, Eiron Cudaback, Nikolas L. Jorstad, Emily Sherfield, Nadia Postupna, Angela Wilson, Martin Darvas, Kathleen S. Montine, C. Dirk Keene, Thomas J. Montine, Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease, Journal of Neuroscience Research, 2015, 93, 9
  10. 10
    Frauke Nees, The nicotinic cholinergic system function in the human brain, Neuropharmacology, 2015, 96, 289

    CrossRef

  11. 11
    Kalyani Kansal, David J. Irwin, The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research, Psychiatric Clinics of North America, 2015, 38, 2, 309

    CrossRef

  12. 12
    Sebastian Schade, Brit Mollenhauer, Biomarkers in biological fluids for dementia with Lewy bodies, Alzheimer's Research & Therapy, 2014, 6, 5-8, 72

    CrossRef

  13. 13
    Félix J. Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín, José A. G. Agúndez, Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease, Frontiers in Cellular Neuroscience, 2014, 8,

    CrossRef

  14. 14
    N. Magdalinou, A. J. Lees, H. Zetterberg, Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 10, 1065

    CrossRef

  15. 15
    Alberto Lleó, Enrica Cavedo, Lucilla Parnetti, Hugo Vanderstichele, Sanna Kaisa Herukka, Niels Andreasen, Roberta Ghidoni, Piotr Lewczuk, Andreas Jeromin, Bengt Winblad, Magda Tsolaki, Barbara Mroczko, Pieter Jelle Visser, Isabel Santana, Per Svenningsson, Kaj Blennow, Dag Aarsland, José Luis Molinuevo, Henrik Zetterberg, Brit Mollenhauer, Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases, Nature Reviews Neurology, 2014, 11, 1, 41

    CrossRef

  16. 16
    Megan K. Herbert, Jorine M. Eeftens, Marjolein B. Aerts, Rianne A.J. Esselink, Bastiaan R. Bloem, H. Bea Kuiperij, Marcel M. Verbeek, CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls, Parkinsonism & Related Disorders, 2014, 20, 1, 112

    CrossRef

  17. 17
    Lucilla Parnetti, Lucia Farotti, Paolo Eusebi, Davide Chiasserini, Claudia De Carlo, David Giannandrea, Nicola Salvadori, Viviana Lisetti, Nicola Tambasco, Aroldo Rossi, Nour K. Majbour, Omar El-Agnaf, Paolo Calabresi, Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef

  18. 18
    Agostino Chiaravalloti, Alessandro Stefani, Alessandro Fiorentini, Annamaria Lacanfora, Paolo Stanzione, Orazio Schillaci, Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease, European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 11, 2137

    CrossRef

  19. 19
    J. E. Lee, K. H. Cho, S. K. Song, H. J. Kim, H. S. Lee, Y. H. Sohn, P. H. Lee, Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease, Journal of Neurology, Neurosurgery & Psychiatry, 2014, 85, 1, 7

    CrossRef

  20. 20
    Stephen N. Gomperts, Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies, Current Neurology and Neuroscience Reports, 2014, 14, 8

    CrossRef

  21. 21
    Shu-yang Yu, Li-jun Zuo, Fang Wang, Ze-jie Chen, Yang Hu, Ya-jie Wang, Xiao-min Wang, Wei Zhang, Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study, BMC Neurology, 2014, 14, 1, 113

    CrossRef

  22. 22
    Dilan Athauda, Thomas Foltynie, The ongoing pursuit of neuroprotective therapies in Parkinson disease, Nature Reviews Neurology, 2014, 11, 1, 25

    CrossRef

  23. 23
    Alice S. Chen-Plotkin, Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases, Neuron, 2014, 84, 3, 594

    CrossRef

  24. 24
    Dana Kim, Jin Hui Paik, Dong-Woon Shin, Hak-Su Kim, Chang-Shin Park, Ju-Hee Kang, What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?, Experimental Neurobiology, 2014, 23, 4, 352

    CrossRef

  25. 25
    Pankaj A. Agarwal, A. Jon Stoessl, Biomarkers for trials of neuroprotection in Parkinson's disease, Movement Disorders, 2013, 28, 1
  26. 26
    Jian Wang, Jake G. Hoekstra, Chuantao Zuo, Travis J. Cook, Jing Zhang, Biomarkers of Parkinson's disease: current status and future perspectives, Drug Discovery Today, 2013, 18, 3-4, 155

    CrossRef

  27. 27
    Mona K. Beyer, Guido Alves, Kristy S. Hwang, Sona Babakchanian, Kolbjorn S. Bronnick, Yi-Yu Chou, Turi O. Dalaker, Martin W. Kurz, Jan P. Larsen, Johanne H. Somme, Paul M. Thompson, Ole-Bjørn Tysnes, Liana G. Apostolova, Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease, Movement Disorders, 2013, 28, 3
  28. 28
    Lucilla Parnetti, Anna Castrioto, Davide Chiasserini, Emanuele Persichetti, Nicola Tambasco, Omar El-Agnaf, Paolo Calabresi, Cerebrospinal fluid biomarkers in Parkinson disease, Nature Reviews Neurology, 2013, 9, 3, 131

    CrossRef

  29. 29
    Jon B. Toledo, Ane Korff, Leslie M. Shaw, John Q. Trojanowski, Jing Zhang, CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease, Acta Neuropathologica, 2013, 126, 5, 683

    CrossRef

  30. 30
    K. Del Tredici, H. Braak, Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia, Journal of Neurology, Neurosurgery & Psychiatry, 2013, 84, 7, 774

    CrossRef

  31. 31
    Jing Zhang, Hayley A. Mattison, Changqin Liu, Carmen Ginghina, Peggy Auinger, Michael P. McDermott, Tessandra Stewart, Un Jung Kang, Kevin C. Cain, Min Shi, Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease, Acta Neuropathologica, 2013, 126, 5, 671

    CrossRef

  32. 32
    Kurt A. Jellinger, Mild cognitive impairment in Parkinson disease: heterogenous mechanisms, Journal of Neural Transmission, 2013, 120, 1, 157

    CrossRef

  33. 33
    A. J. Yarnall, L. Rochester, D. J. Burn, Mild cognitive impairment in Parkinson's disease, Age and Ageing, 2013, 42, 5, 567

    CrossRef

  34. 34
    David J. Irwin, Virginia M.-Y. Lee, John Q. Trojanowski, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nature Reviews Neuroscience, 2013, 14, 9, 626

    CrossRef

  35. 35
    Sun Ah Park, Jung Hun Kim, Hyeong Jun Kim, Tae Eun Kim, Yoon-Jeong Kim, Dong Hyun Lee, Jeong Ho Park, Won Seok Chae, Soo Jae Yim, Sang Won Seo, Duk L. Na, Seong Hye Choi, Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers, Dementia and Neurocognitive Disorders, 2013, 12, 1, 1

    CrossRef

  36. 36
    Yaroslau Compta, Tamas Revesz, Andrew J. Lees, The more cortical amyloid-β, the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?, Movement Disorders, 2013, 28, 3
  37. 37
    Jing Zhang, Tessandra Stewart, Genomic and Personalized Medicine, 2013,

    CrossRef

  38. 38
    Andrew Siderowf, Parkinson’s Disease: Diagnosis, Motor Symptoms and Non-Motor Features, 2013,

    CrossRef

  39. 39
    Per Svenningsson, Eric Westman, Clive Ballard, Dag Aarsland, Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment, The Lancet Neurology, 2012, 11, 8, 697

    CrossRef

  40. 40
    Alessandro Stefani, Livia Brusa, Enrica Olivola, Mariangela Pierantozzi, Alessandro Martorana, CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD, Journal of Neural Transmission, 2012, 119, 7, 861

    CrossRef

  41. 41
    Kurt A. Jellinger, CSF biomarkers in different phenotypes of Parkinson disease, Journal of Neural Transmission, 2012, 119, 4, 455

    CrossRef

  42. 42
    Yaroslau Compta, Naroa Ibarretxe-Bilbao, Joana B. Pereira, Carme Junqué, Núria Bargalló, Eduardo Tolosa, Francesc Valldeoriola, Esteban Muñoz, Ana Camara, Mariateresa Buongiorno, Maria Jose Martí, Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia, Parkinsonism & Related Disorders, 2012, 18, 8, 941

    CrossRef

  43. 43
    Kurt A Jellinger, Neurobiology of cognitive impairment in Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 12, 1451

    CrossRef

  44. 44
    Ji E. Lee, Kyoo H. Cho, Myonghwan Kim, Young H. Sohn, Phil Hyu Lee, The pattern of cortical atrophy in Parkinson’s disease with mild cognitive impairment according to the timing of cognitive dysfunction, Journal of Neurology, 2012, 259, 3, 469

    CrossRef

  45. 45
    Kurt Jellinger, The role of α-synuclein in neurodegeneration — An update, Translational Neuroscience, 2012, 3, 2

    CrossRef

  46. 46
    Mariateresa Buongiorno, Yaroslau Compta, Maria J. Martí, Amyloid-β and τ biomarkers in Parkinson's disease–dementia, Journal of the Neurological Sciences, 2011, 310, 1-2, 25

    CrossRef

  47. 47
    Min Shi, Joshua Bradner, Aneeka M. Hancock, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, Hojoong M. Kim, James B. Leverenz, Thomas J. Montine, Carmen Ginghina, Un Jung Kang, Kevin C. Cain, Yu Wang, Jan Aasly, David Goldstein, Jing Zhang, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Annals of Neurology, 2011, 69, 3
  48. 48
    Yu Wang, Aneeka M. Hancock, Joshua Bradner, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, Hojoong M. Kim, James B. Leverenz, Thomas J. Montine, Carmen Ginghina, Karen L. Edwards, Katherine W. Snapinn, David S. Goldstein, Min Shi, Jing Zhang, Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy, The American Journal of Pathology, 2011, 178, 4, 1509

    CrossRef

  49. 49
    Min Shi, Jing Zhang, CSF α-synuclein, tau, and amyloid β in Parkinson's disease, The Lancet Neurology, 2011, 10, 8, 681

    CrossRef

  50. 50
    Thomas J. Montine, Parkinson disease: PD biomarkers—use of α-synuclein reaches new levels, Nature Reviews Neurology, 2011, 7, 6, 308

    CrossRef

  51. 51
    Luis F. Gonzalez-Cuyar, Joshua A. Sonnen, Kathleen S. Montine, C. Dirk Keene, Thomas J. Montine, Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment, Current Neurology and Neuroscience Reports, 2011, 11, 5, 455

    CrossRef

  52. 52
    Kenneth Marek, Danna Jennings, Shirley Lasch, Andrew Siderowf, Caroline Tanner, Tanya Simuni, Chris Coffey, Karl Kieburtz, Emily Flagg, Sohini Chowdhury, Werner Poewe, Brit Mollenhauer, Paracelsus-Elena Klinik, Todd Sherer, Mark Frasier, Claire Meunier, Alice Rudolph, Cindy Casaceli, John Seibyl, Susan Mendick, Norbert Schuff, Ying Zhang, Arthur Toga, Karen Crawford, Alison Ansbach, Pasquale De Blasio, Michele Piovella, John Trojanowski, Les Shaw, Andrew Singleton, Keith Hawkins, Jamie Eberling, Deborah Brooks, David Russell, Laura Leary, Stewart Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David Standaert, Stephanie Guthrie, Robert Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltan Mari, Melissa Gerstenhaber, David Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor Grachev, Kim Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor, The Parkinson Progression Marker Initiative (PPMI), Progress in Neurobiology, 2011, 95, 4, 629

    CrossRef